MCID: PST011
MIFTS: 51

Pustulosis of Palm and Sole

Categories: Skin diseases

Aliases & Classifications for Pustulosis of Palm and Sole

MalaCards integrated aliases for Pustulosis of Palm and Sole:

Name: Pustulosis of Palm and Sole 12 15
Psoriasis 44 72
Pustular Psoriasis of the Palms and/or Soles 12
Acrodermatitis Continua of Hallopeau 72
Generalized Pustular Psoriasis 72
Pustulosis of Palms and Soles 72
Palmoplantar Pustulosis 12
Acropustulosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4398
MeSH 44 D011565
NCIt 50 C34888
SNOMED-CT 68 27520001
ICD10 33 L40.3
UMLS 72 C0030246 C0033860 C0343055 more

Summaries for Pustulosis of Palm and Sole

MalaCards based summary : Pustulosis of Palm and Sole, also known as psoriasis, is related to impetigo herpetiformis and psoriasis 14, pustular, and has symptoms including pruritus, exanthema and psoriasiform rash. An important gene associated with Pustulosis of Palm and Sole is MRAP (Melanocortin 2 Receptor Accessory Protein), and among its related pathways/superpathways are NF-KappaB Family Pathway and Innate Lymphoid Cell Differentiation Pathways. The drugs Esomeprazole and Dapsone have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and testes.

Related Diseases for Pustulosis of Palm and Sole

Diseases related to Pustulosis of Palm and Sole via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1222)
# Related Disease Score Top Affiliating Genes
1 impetigo herpetiformis 33.0 IL36RN CARD14
2 psoriasis 14, pustular 32.5 IL36RN AP1S3
3 geographic tongue 32.4 TNF IL36RN
4 spondylitis 31.1 TNFRSF1B TNF
5 pustular psoriasis 31.1 TNF IL36RN CARD14 AP1S3
6 psoriasis 31.0 TNF IL36RN CARD14
7 pustulosis palmaris et plantaris 30.9 TNF IL36RN CCR6 AP1S3
8 bone inflammation disease 30.9 TNFRSF1B TNF MRAP
9 tenosynovitis 30.6 TNFRSF1B MRAP
10 nasopharyngitis 30.6 TNFRSF1B IL36RN
11 skin disease 30.5 TNF IL36RN CARD14
12 spondyloarthropathy 1 30.4 TNFRSF1B TNF MRAP
13 iritis 30.4 TNFRSF1B MRAP
14 psoriatic arthritis 30.4 TNFRSF1B TNF IL36RN
15 pityriasis rubra pilaris 30.4 TNFRSF1B IL36RN CARD14
16 pyoderma 30.3 TNF IL36RN
17 acrodermatitis 30.2 IL36RN AP1S3
18 exanthem 30.2 TNFRSF1B TNF
19 subcorneal pustular dermatosis 30.2 TNFRSF1B IL36RN
20 skin sarcoidosis 30.0 TNFRSF1B TNF
21 orbital plasma cell granuloma 29.9 TNFRSF1B MRAP
22 posterior scleritis 29.6 TNF MRAP
23 panuveitis 29.4 TNFRSF1B TNF MRAP
24 periodic fever, familial, autosomal dominant 29.4 TNFRSF1B TNF
25 guillain-barre syndrome 29.4 TNFRSF1B TNF
26 juvenile rheumatoid arthritis 29.3 TNFRSF1B TNF
27 melkersson-rosenthal syndrome 29.2 TNFRSF1B TNF
28 palindromic rheumatism 29.1 TNFRSF1B TNF MRAP
29 behcet syndrome 29.0 TNFRSF1B TNF MRAP
30 psoriasis 13 12.7
31 psoriasis 7 12.7
32 psoriasis 11 12.7
33 psoriasis 2 12.6
34 psoriasis 15, pustular 12.6
35 psoriasis 4 12.6
36 psoriasis 3 12.6
37 psoriasis 10 12.6
38 psoriasis 6 12.5
39 psoriasis 5 12.5
40 psoriasis 12 12.5
41 psoriasis 8 12.5
42 psoriasis 9 12.5
43 mental retardation and psoriasis 12.3
44 tranebjaerg svejgaard syndrome 12.1
45 psoriatic juvenile idiopathic arthritis 11.9
46 psoriasis 1 11.7
47 parapsoriasis 11.5
48 vitiligo-associated multiple autoimmune disease susceptibility 1 11.5
49 subacute cutaneous lupus erythematosus 11.4
50 temporomandibular ankylosis 11.4

Graphical network of the top 20 diseases related to Pustulosis of Palm and Sole:



Diseases related to Pustulosis of Palm and Sole

Symptoms & Phenotypes for Pustulosis of Palm and Sole

UMLS symptoms related to Pustulosis of Palm and Sole:


pruritus, exanthema, psoriasiform rash

Drugs & Therapeutics for Pustulosis of Palm and Sole

Drugs for Pustulosis of Palm and Sole (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 467)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Esomeprazole Approved, Investigational Phase 4 119141-88-7, 161796-78-7, 161973-10-0 9568614 4594
2
Dapsone Approved, Investigational Phase 4 80-08-0 2955
3
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051
4
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
5
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
6
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
7
Clocortolone Approved Phase 4 34097-16-0, 4828-27-7 5282493 5311052
8
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
9
Sodium citrate Approved, Investigational Phase 4 68-04-2
10
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
11
carbamide peroxide Approved Phase 4 124-43-6
12 Orange Approved Phase 4
13 Strawberry Approved Phase 4
14 Artichoke Approved Phase 4
15
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
16
Adalimumab Approved Phase 4 331731-18-1 16219006
17
Certolizumab pegol Approved Phase 4 428863-50-7
18
Desoximetasone Approved Phase 4 382-67-2 5311067
19
Tofacitinib Approved, Investigational Phase 4 477600-75-2
20
Zinc Approved, Investigational Phase 4 7440-66-6 32051
21
Mercaptopurine Approved Phase 4 50-44-2 667490
22
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
23
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
24 Ixekizumab Approved, Investigational Phase 4 1143503-69-8
25
tannic acid Approved Phase 4 1401-55-4
26
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
27
Ustekinumab Approved, Investigational Phase 4 815610-63-0
28
Metformin Approved Phase 4 657-24-9 4091 14219
29 Vedolizumab Approved Phase 4 943609-66-3
30
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
31
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
32
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
33
Capsaicin Approved Phase 4 404-86-4 1548943
34
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
35
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
36
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
37
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
38
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
39 Retinol palmitate Phase 4
40 retinol Phase 4
41 Antiparasitic Agents Phase 4
42 Antiprotozoal Agents Phase 4
43 Antimalarials Phase 4
44 Tin Fluorides Phase 4
45 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
46 Immunoglobulin A Phase 4
47 Halobetasol Phase 4
48
Chondroitin Phase 4 9007-27-6 53477707
49 Hydrocortisone 17-butyrate 21-propionate Phase 4
50 Hydrocortisone hemisuccinate Phase 4

Interventional clinical trials:

(show top 50) (show all 1555)
# Name Status NCT ID Phase Drugs
1 Improvement in the Quality of Life of Patients With Severe Plaque Psoriasis Treated With Systemic Methotrexate in Fixed Doses of 10mg or 25mg Orally Once Weekly: a Prospective, Randomized, Double-blind, Parallel Group Study. Unknown status NCT02248792 Phase 4 Methotrexate
2 A Phase4,Multicenter, Randomized,Double-blind,Double Dummy, Parallel Controlled Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Treatment of Chinese Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01443338 Phase 4 Triptergium Wilfordii;Acitretin
3 The Difference of Circulating Endothelial-derived and Platelet-derived Microparticles in Patients With Psoriasis Successfully Treated With Stelara(Ustekinumab) Unknown status NCT02693470 Phase 4 Ustekinumab
4 Proton Pump Inhibitors Use in Patients With Psoriasis Unknown status NCT02624544 Phase 4 esomeprazole;desonide
5 Phase IV Study on Efficacy and Safety of the Combination Treatment Acitretin and Efalizumab in Moderate to Severe Chronic Plaque Psoriasis Unknown status NCT00707070 Phase 4 efalizumab plus placebo;efalizumab plus acitretin
6 An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
7 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%
8 An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use Unknown status NCT01132235 Phase 4
9 The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
10 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
11 A Double - Blind, Placebo Controlled Crossover Study to Evaluate The Efficacy and Tolerability of Stelara ™ (Ustekinumab) in The Treatment of Scalp Psoriasis Unknown status NCT01558310 Phase 4 Ustekinumab;Placebo
12 Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After Adalimumab Therapy Unknown status NCT01237262 Phase 4 Adalimumab, etanercept, infliximab
13 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis Unknown status NCT01223976 Phase 4
14 The Effect of Vitamin A Supplementation on CD4+ T-cell Secretion in Obese Individuals Unknown status NCT01405352 Phase 4
15 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
16 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Treating Scalp Involvement in Subjects With Moderate to Severe Plaque Psoriasis Completed NCT00791765 Phase 4
17 A Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etanercept in the Treatment of Subjects With Psoriasis Completed NCT00195507 Phase 4 Etanercept
18 Canadian Assessment of Patient Outcomes and Effectiveness of Enbrel (Etanercept) in Psoriasis Completed NCT00332332 Phase 4
19 A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis Completed NCT00663052 Phase 4 Etanercept;Etanercept
20 Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05% Completed NCT01893567 Phase 4 Clobex Spray
21 A Multicenter, Open-label, Randomized, Pilot-study to Evaluate the Efficacy and Safety of the Combination of Etanercept (ETN) and Methotrexate and of Etanercept (ETN) Alone in Patients With Plaque Psoriasis Despite Methotrexate Therapy Completed NCT00161655 Phase 4 Etanercept;Methotrexate
22 A Randomized Pilot Study Evaluating the Efficacy and Safety of Etanercept in Patients With Moderate to Severe Plaque Psoriasis After Cessation of Ciclosporin Therapy Completed NCT00581555 Phase 4 Etanercept
23 Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate: a Phase IV, Multicenter, Randomized, Double-blind, Controlled Trial Completed NCT02313922 Phase 4 etanercept combined with methotrexate or etanercept combined with placebo
24 An Open-Label Phase 4 Study in Adult Patients With Chronic Plaque Psoriasis to Evaluate the Immune Response to Pneumococcal Vaccine in Subjects Treated With Alefacept Completed NCT00493324 Phase 4 alefacept;polyvalent pneumococcal vaccine
25 Elocon vs Fluticasone in Localized Psoriasis Completed NCT00763529 Phase 4 Mometasone;Fluticasone
26 Fase IV Clinical Trial to Evaluate Chondroitin Sulphate Efficacy and Safety in Patients With Knee Osteoarthritis and Psoriasis Completed NCT00669123 Phase 4 Chondroitin sulphate;Placebo
27 Evaluating Safety in Patients With Moderate to Severe Psoriasis Treated With Etanercept Completed NCT00581165 Phase 4 Etanercept
28 Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population Completed NCT02533973 Phase 4 Xamiol® gel;Daivonex® scalp solution
29 Efficacy and Safety of Alefacept in Combination With Narrow-band UVB (nbUVB) Compared to Alefacept Alone in Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed NCT00658606 Phase 4 alefacept
30 An Open-Label, Study Evaluating Topicort® Topical Spray 0.25% (Desoximetasone) in Patients With Scalp Psoriasis Completed NCT02985736 Phase 4 Topicort Topical Spray
31 A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Completed NCT00287118 Phase 4 Efalizumab
32 An Open-Label, Multicenter Study of the Efficacy of Cloderm® Cream (Clocortolone Pivalate, 0.1%) in the Treatment of Moderate Plaque Psoriasis for 28 Days Completed NCT01714544 Phase 4 Cloderm Cream
33 A Randomised, Double-Blind, Active-Controlled, Parallel, Multi-Center Study to Investigate the Efficacy and Safety of Daivobet® Ointment in Patients With Psoriasis Vulgaris Completed NCT00248456 Phase 4 Calcipotriol plus betamethasone dipropionate ointment
34 A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild to Moderate Psoriasis Vulgaris. Completed NCT02733874 Phase 4 Compound Clobetasol Propionate Ointment;Calcipotriol Betamethasone Ointment
35 Safety and Efficacy of Etanercept in Patients With Moderate to Severe Plaque Psoriasis Who Have Shown an Unsatisfactory Response to Adalimumab or Infliximab Completed NCT00967538 Phase 4 etanercept 50 mg
36 An Open Label, Non-comparative, Multicentre, Phase IV Study to Evaluate the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis Completed NCT01373567 Phase 4 TINEFCON
37 A Single-Center, Open-Label Study to Assess Change in Psychosocial and Occupational Dimensions With Ustekinumab Treatment of Moderate-to-Severe Psoriasis Evaluated With the Psychological General Well Being (PGWB), Work Productivity and Activity Impairment (WPAI), Psoriasis Quality of Life-12 Items (PQOL-12), and Dermatology Life Quality Index (DLQI) Completed NCT01511315 Phase 4 Ustekinumab
38 A Study to Evaluate the Efficacy and Tolerability of Clobetasol Propionate vs. Vehicle in the Treatment of Mild to Moderate Plaque-Type Psoriasis Completed NCT00842153 Phase 4 Clobetasol propionate foam;Vehicle foam
39 A Single-arm Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Subjects With Plaque Psoriasis Completed NCT02274792 Phase 4 Etanercept
40 A PHASE IV, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF USTEKINUMAB ON VASCULAR INFLAMMATION IN PSORIASIS Completed NCT02187172 Phase 4 Ustekinumab;Placebo
41 A Multicenter, Open-Label, Pilot Trial to Evaluate the Effectiveness and Safety of ENBREL(r) in Combination With Narrowband UVB Phototherapy for the Treatment of Psoriasis Completed NCT00110981 Phase 4 Etanerept;Etanercept
42 A Study to Evaluate Safety and Efficacy of Clobetasol Propionate for Treatment of Plaque-Type Psoriasis in Adult Subjects. Completed NCT00852761 Phase 4 Olux-E Foam;Clobex lotion
43 Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast Completed NCT02749370 Phase 4 Etanercept
44 Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis Completed NCT01766440 Phase 4 Calcitriol 3 mcg/g ointment
45 An Evaluation of the Efficacy, Safety, Preference and Duration of Response of Clobex® (Clobetasol Propionate) Spray and Taclonex® (Calcipotriene 0.05%/Betamethasone Dipropionate 0.064%) Ointment in Subjects With Stable Plaque Psoriasis Completed NCT00437255 Phase 4 Clobetasol Propionate, 0.05%;Calcipotriene and betamethasone dipropionate ointment
46 A Comparison Between Clobetasol Propionate (Clobex®) Spray and Clobetasol Propionate (Olux®) Foam With Regard to Efficacy, Safety, Preference and Duration of Response in Stable Plaque Psoriasis Completed NCT00436540 Phase 4 Clobetasol Propionate 0.05% Spray;Clobetasol Propionate 0.05% Foam
47 Efficacy and Safety of Methotrexate in 2 Fixed Doses of 10mg or 25mg Orally Once Weekly in Patients With Severe Plaque Type Psoriasis: a Prospective, Randomized, Double Blind, Dose Ranging Study Completed NCT01187264 Phase 4 Methotrexate
48 Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice Completed NCT01147874 Phase 4
49 An Open -Label Study to Evaluate the Effect of Pandel Cream 0.1% on the Hypothalamic Pituitary Adrenal Axis in the Pediatric and Adult Population Completed NCT01137032 Phase 4 Pandel Cream 0.1%
50 Randomised, Open-label Preliminary Study to Assess the Effects of 2 Regimens of Etanercept on Nail and Skin Symptoms in Patients With Nail Psoriasis and Plaque Psoriasis Completed NCT00581100 Phase 4 etanercept

Search NIH Clinical Center for Pustulosis of Palm and Sole

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Acitretin
alefacept
Aloe vera preparation
Anthralin
ANTHRALIN PWDR
Betamethasone
Betamethasone acetate
Betamethasone benzoate
betamethasone dipropionate
betamethasone sodium phosphate
Betamethasone valerate
BETAMETHASONE VALERATE PWDR
calcipotriene
Calcitriol
Cholecalciferol
Coal Tar
Coal tar extract
Coal tar pitch volatiles
COAL TAR,COLLOIDAL
COAL TAR,REFINED
Cod Liver Oil
Colloid sulfur
Cyclosporine
Etretinate
Fish Liver Oils
fluocinolone
Fluocinolone Acetonide
hydroxyurea
Methotrexate
Methotrexate Sodium
Methoxsalen
mycophenolate mofetil
mycophenolate mofetil hydrochloride
Salicylic Acid
SALICYLIC ACID PWDR
Sulfur
SULFUR PWDR
SULFUR,COLLOIDAL
tazarotene
Thioguanine
Trioxsalen

Cochrane evidence based reviews: psoriasis

Genetic Tests for Pustulosis of Palm and Sole

Anatomical Context for Pustulosis of Palm and Sole

MalaCards organs/tissues related to Pustulosis of Palm and Sole:

41
Skin, T Cells, Testes, Liver, Neutrophil, Endothelial, Bone

Publications for Pustulosis of Palm and Sole

Articles related to Pustulosis of Palm and Sole:

(show top 50) (show all 30000)
# Title Authors PMID Year
1
JAK-inhibitors in dermatology: current evidence and future applications. 38
30433838 2019
2
Patient preferences for attributes of topical anti-psoriatic medicines. 38
30470146 2019
3
Special aspects of biologics treatment in psoriasis: management in pregnancy, lactation, surgery, renal impairment, hepatitis and tuberculosis. 38
30428753 2019
4
Efficacy and safety of pioglitazone plus phototherapy versus phototherapy in patients with plaque type psoriasis: a Double Blinded Randomized Controlled Trial. 38
30394148 2019
5
Anti-psoriasis effect of water-processed rosin in mice. 38
31288049 2019
6
Total glucosides of paeony attenuates animal psoriasis induced inflammatory response through inhibiting STAT1 and STAT3 phosphorylation. 38
31356966 2019
7
Necrotizing Granulomas in a Patient With Psoriasis and Sarcoidosis After Adalimumab-Medication-Induced Reaction or Reactivation of Latent Disease? 38
30839343 2019
8
Challenges in the treatment of psoriasis with biologics: vaccination, history of malignancy, human immunodeficiency virus (HIV) infection, and pediatric psoriasis. 38
30891751 2019
9
Mycosis fungoides with spongiosis: A potential diagnostic pitfall. 38
30989664 2019
10
Assessing Efficacy and the Speed of Response in Psoriasis Treatment. 38
31339413 2019
11
Efficacy and survival of biologic agents in psoriasis: a practical real-life 12-year experience in a French dermatology department. 38
29848153 2019
12
Sleep disorders in patients with psoriasis: a cross-sectional study using non-polysomnographical methods. 38
30859369 2019
13
A Real-World, Non-interventional Indian Study Evaluating Intensive Plant-Based Butter Moisturizing Cream in Psoriasis. 38
31201712 2019
14
Psoriatic Arthritis: What is Happening at the Joint? 38
31102105 2019
15
Biological treatment for psoriasis and the risk of herpes zoster: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). 38
29619848 2019
16
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. 38
31351884 2019
17
Colloidal nanostructured lipid carriers of pentoxifylline produced by microwave irradiation ameliorates imiquimod-induced psoriasis in mice. 38
31170645 2019
18
Poor medication adherence in patients with psoriasis and a successful intervention. 38
29790405 2019
19
YouTube videos on oral systemic therapies for psoriasis: a cross-sectional analysis. 38
30457412 2019
20
Comment on "Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study". 38
31112727 2019
21
Narrowband UVB treatment induces expression of WNT7B, WNT10B and TCF7L2 in psoriasis skin. 38
31089877 2019
22
Factors Influencing Sleep Difficulty and Sleep Quantity in the Citizen Pscientist Psoriatic Cohort. 38
31177381 2019
23
ERAPSO: Revealing the High Burden of Obesity in German Psoriasis Patients. 38
31297711 2019
24
The incidence of anxiety may not be correlated with severity of psoriasis: A prospective pilot study. 38
31383329 2019
25
Economic Impact of Etanercept in Patients with Psoriasis and Psoriatic Arthritis in Spain: A Systematic Review. 38
31062222 2019
26
The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. 38
31113794 2019
27
Lack of association of biologic therapy for psoriasis with psychiatric illness: An electronic medical records cohort study. 38
31054973 2019
28
Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed. 38
31078609 2019
29
Reply to: "Comment on 'Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study'". 38
31112724 2019
30
Efficacy of a Topical Formulation of Sodium Bicarbonate in Mild to Moderate Stable Plaque Psoriasis: a Randomized, Blinded, Intrapatient, Controlled Study. 38
31077089 2019
31
Remission Duration and Long-Term Outcomes in Patients with Moderate-to-Severe Psoriasis Treated by Biologics or Tofacitinib in Controlled Clinical Trials: A 15-Year Single-Center Experience. 38
31270683 2019
32
Vasoconstrictor potency of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam versus other topical corticosteroids used to treat psoriasis vulgaris. 38
30582717 2019
33
Adherence to the Mediterranean diet is independently associated with psoriasis risk, severity, and quality of life: a cross-sectional observational study. 38
31168780 2019
34
Preclinical development of GR1501, a human monoclonal antibody that neutralizes interleukin-17A. 38
31353088 2019
35
Serum YKL-40 in patients with psoriasis vulgaris treated by narrow-band UVB phototherapy. 38
30482111 2019
36
Circulating levels of chemokines in patients with psoriasis vulgaris and their association with disease severity: A case-control study from North India. 38
31389369 2019
37
Nanostructured supramolecular hydrogels: Towards the topical treatment of Psoriasis and other skin diseases. 38
31212138 2019
38
Judicial precedents on medicolegal disputes arising from psoriasis treatment in South Korea. 38
31389366 2019
39
Expression and correlation of interleukin-36γ, claudin-1 and claudin-7 in psoriasis. 38
31322135 2019
40
Developing a preference-based utility scoring algorithm for the Psoriasis Area Severity Index (PASI). 38
31161828 2019
41
Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: A case series. 38
31389375 2019
42
Guselkumab in the Treatment of Concomitant Hidradenitis Suppurativa, Psoriasis, and Crohn's Disease. 38
31389737 2019
43
Old is gold? Retrospective evaluation of efficacy and safety of topical psoralen-ultraviolet A phototherapy for palmoplantar psoriasis and dermatitis. 38
31001823 2019
44
Developing an online patient education resource for topical therapy: a pilot study. 38
31420862 2019
45
Insomnia and other sleep complaints in inflammatory versus noninflammatory skin disorders: An observational case-control study. 38
31168791 2019
46
Epidemiology and Comorbidities of Psoriasis among Israeli Adolescents: A Large Cross-Sectional Study. 38
31390627 2019
47
Increased risk of psoriasis in subjects with abdominal obesity: A nationwide population-based study. 38
31149744 2019
48
Can we better strategize our choice of pharmacotherapy for patients with co-morbid psoriasis and obesity? 38
31002541 2019
49
Aryl hydrocarbon receptor polymorphisms are associated with dry skin phenotypes in Chinese patients with atopic dermatitis. 38
30499126 2019
50
Gluten intake and risk of psoriasis, psoriatic arthritis and atopic dermatitis among US women. 38
31404570 2019

Variations for Pustulosis of Palm and Sole

Expression for Pustulosis of Palm and Sole

Search GEO for disease gene expression data for Pustulosis of Palm and Sole.

Pathways for Pustulosis of Palm and Sole

GO Terms for Pustulosis of Palm and Sole

Biological processes related to Pustulosis of Palm and Sole according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.67 TNFRSF1B TNF IL36RN
2 cytokine-mediated signaling pathway GO:0019221 9.54 TNFRSF1B TNF IL36RN
3 positive regulation of JNK cascade GO:0046330 9.51 TNF IL36RN
4 positive regulation of interleukin-6 production GO:0032755 9.48 TNF IL36RN
5 humoral immune response GO:0006959 9.46 TNF CCR6
6 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.43 TNFRSF1B TNF
7 cellular response to lipopolysaccharide GO:0071222 9.43 TNFRSF1B TNF IL36RN
8 extrinsic apoptotic signaling pathway GO:0097191 9.4 TNFRSF1B TNF
9 negative regulation of interleukin-6 production GO:0032715 9.32 TNF IL36RN
10 immune response GO:0006955 9.26 TNFRSF1B TNF IL36RN CCR6
11 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.16 TNFRSF1B TNF
12 tumor necrosis factor-mediated signaling pathway GO:0033209 8.8 TNFRSF1B TNF CARD14

Sources for Pustulosis of Palm and Sole

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....